BACKGROUND: Annual mass treatment with albendazole and ivermectin is the mainstay of current strategies to interrupt transmission of Wuchereria bancrofti in Africa. More-effective microfilarial suppression could potentially reduce the time necessary to interrupt transmission, easing the economic burden of mass treatment programs in countries with limited resources. METHODS: To determine the effect of increased dose and frequency of albendazole-ivermectin treatment on microfilarial clearance, 51 W. bancrofti microfilaremic residents of an area of W. bancrofti endemicity in Mali were randomized to receive 2 doses of annual, standard-dose albendazole-ivermectin therapy (400 mg and 150 μg/kg; n = 26) or 4 doses of twice-yearly, increased-dose albendazole-ivermectin therapy (800 mg and 400 μg/kg; n = 25). RESULTS: Although microfilarial levels decreased significantly after therapy in both groups, levels were significantly lower in the high-dose, twice-yearly group at 12, 18, and 24 months. Furthermore, there was complete clearance of detectable microfilariae at 12 months in the 19 patients in the twice-yearly therapy group with data available at 12 months, compared with 9 of 21 patients in the annual therapy group (P < .001, by Fisher's exact test). This difference between the 2 groups was sustained at 18 and 24 months, with no detectable microfilariae in the patients receiving twice-yearly treatment. Worm nests detectable by ultrasonography and W. bancrofti circulating antigen levels, as measured by enzyme-linked immunosorbent assay, were decreased to the same degree in both groups at 24 months, compared with baseline. CONCLUSIONS: These findings suggest that increasing the dosage and frequency of albendazole-ivermectin treatment enhances suppression of microfilariae but that this effect may not be attributable to improved adulticidal activity.
RCT Entities:
BACKGROUND: Annual mass treatment with albendazole and ivermectin is the mainstay of current strategies to interrupt transmission of Wuchereria bancrofti in Africa. More-effective microfilarial suppression could potentially reduce the time necessary to interrupt transmission, easing the economic burden of mass treatment programs in countries with limited resources. METHODS: To determine the effect of increased dose and frequency of albendazole-ivermectin treatment on microfilarial clearance, 51 W. bancrofti microfilaremic residents of an area of W. bancrofti endemicity in Mali were randomized to receive 2 doses of annual, standard-dose albendazole-ivermectin therapy (400 mg and 150 μg/kg; n = 26) or 4 doses of twice-yearly, increased-dose albendazole-ivermectin therapy (800 mg and 400 μg/kg; n = 25). RESULTS: Although microfilarial levels decreased significantly after therapy in both groups, levels were significantly lower in the high-dose, twice-yearly group at 12, 18, and 24 months. Furthermore, there was complete clearance of detectable microfilariae at 12 months in the 19 patients in the twice-yearly therapy group with data available at 12 months, compared with 9 of 21 patients in the annual therapy group (P < .001, by Fisher's exact test). This difference between the 2 groups was sustained at 18 and 24 months, with no detectable microfilariae in the patients receiving twice-yearly treatment. Worm nests detectable by ultrasonography and W. bancrofti circulating antigen levels, as measured by enzyme-linked immunosorbent assay, were decreased to the same degree in both groups at 24 months, compared with baseline. CONCLUSIONS: These findings suggest that increasing the dosage and frequency of albendazole-ivermectin treatment enhances suppression of microfilariae but that this effect may not be attributable to improved adulticidal activity.
Authors: Moses J Bockarie; Daniel J Tisch; Will Kastens; Neal D E Alexander; Zachary Dimber; Florence Bockarie; Ervin Ibam; Michael P Alpers; James W Kazura Journal: N Engl J Med Date: 2002-12-05 Impact factor: 91.245
Authors: D G Addiss; M J Beach; T G Streit; S Lutwick; F H LeConte; J G Lafontant; A W Hightower; P J Lammie Journal: Lancet Date: 1997-08-16 Impact factor: 79.321
Authors: Merepen A Guindo; Joseph P Shott; Renion Saye; Moussa L Diakité; Sintry Sanogo; Moussa B Dembele; Sekouba Keita; Mary C Nagel; Ruth D Ellis; Joan A Aebig; Dapa A Diallo; Ogobara K Doumbo Journal: Am J Trop Med Hyg Date: 2012-04 Impact factor: 2.345
Authors: Sébastien D S Pion; Cédric B Chesnais; Jean Bopda; Frédéric Louya; Peter U Fischer; Andrew C Majewski; Gary J Weil; Michel Boussinesq; François Missamou Journal: Am J Trop Med Hyg Date: 2015-03-09 Impact factor: 2.345
Authors: Frank O Richards; Abel Eigege; Emmanuel S Miri; Alphonsus Kal; John Umaru; Davou Pam; Lindsay J Rakers; Yohanna Sambo; Jacob Danboyi; Bako Ibrahim; Solomon E Adelamo; Gladys Ogah; Danjuma Goshit; O Kehinde Oyenekan; Els Mathieu; P Craig Withers; Yisa A Saka; Jonathan Jiya; Donald R Hopkins Journal: PLoS Negl Trop Dis Date: 2011-10-11
Authors: Kevin C Kobylinski; Ratawan Ubalee; Alongkot Ponlawat; Chanyapat Nitatsukprasert; Siriporn Phasomkulsolsil; Thanaporn Wattanakul; Joel Tarning; Kesara Na-Bangchang; Patrick W McCardle; Silas A Davidson; Jason H Richardson Journal: Malar J Date: 2017-07-07 Impact factor: 2.979
Authors: Roland Oscar; Jean Frantz Lemoine; Abdel Nasser Direny; Luccene Desir; Valery E Madsen Beau de Rochars; Mathieu J P Poirier; Ann Varghese; Ijeoma Obidegwu; Patrick J Lammie; Thomas G Streit; Marie Denise Milord Journal: PLoS Negl Trop Dis Date: 2014-07-17